We have recently added 12 venture funded companies to our M&A analysis of European therapeutic companies acquired post-IPO. As expected, those companies were acquired at a later developed stage.
As previously highlighted most European venture capital funded therapeutic companies are acquired after receiving less than EUR 45M in venture capital funding ().
Does this observation indicate that if an M&A is not in place before EUR 45M invested, then an IPO is necessary to develop the company into an interesting M&A opportunity?
Does this highlight how dependent European Life Science Venture Capital is on a well-functioning public market to benchmark with our US colleagues?
Today we are listing Galecto Biotech on NASDAQ – and hope that in few years we can include a Galecto Biotech M&A in our M&A analysis :-). Until then, well done and good luck to Hans T. Schambye and his team.